Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion type Assertion NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_head.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion wasGeneratedBy ECO_0000203 NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_provenance.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion wasDerivedFrom befree-20140225 NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_provenance.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion SIO_000772 15621812 NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_provenance.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion evidence source_evidence_literature NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_provenance.
- NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_assertion description "[Imatinib, the ABL kinase inhibitor, is used not only for Philadelphia chromosome-positive (Ph + ) chronic myelogenous leukemia, but also for Ph + acute lymphoblastic leukemia (ALL), although resistance to the drug tends to develop in an early stage of the clinical course.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP520656.RAX658lOuIQjttURVk2-EYv-ECaBz5-LvbO8yXZQeRdAg130_provenance.